Eight updates in multiple myeloma

The International Myeloma Foundation declared March as Myeloma Awareness Month in 2009. Since then, the foundation has rebranded the program, now called “Myeloma Action Month,” to encourage health care professionals, patient advocates and caregivers to “take action to empower patients and arm them with knowledge.”

In conjunction with Myeloma Action Month, HemOnc Today presents eight updates in the treatment of multiple myeloma that may affect your practice.

  • The FDA placed a partial clinical hold on all clinical trials — including those for myeloma — designed to evaluate selinexor (KPT-330, Karyopharm Therapeutics), a first-in-class, oral selective inhibitor of nuclear export compound. Read more.
  • HemOnc Today spoke with physicians and researchers — as well as representatives of The Institute for Clinical and Economic Review (ICER) and the pharmaceutical industry — about advances in myeloma therapy and what they mean for patients, how a recently published ICER report can help guide treatment decision-making, and whether concerns that the report may limit insurance coverage of myeloma drugs are valid. Read more.
  • The phase 2 trial designed to evaluate galinpepimut-S (Sellas Life Sciences) for the treatment of multiple myeloma demonstrated a clinical benefit in high-risk patients following autologous stem cell transplantation. Read more.
  • Back pain occurring with abnormal lab results, weight loss or fatigue should alert clinicians to the possibility of multiple myeloma. Read more.
  • The combination of carfilzomib (Kyprolis, Amgen) and dexamethasone significantly extended OS compared with bortezomib (Velcade, Takeda Oncology) and dexamethasone, according to results of a planned interim analysis of the phase 3 ENDEAVOR trial. Read more.
  • The FDA expanded the approval of lenalidomide (Revlimid, Celgene) to include maintenance therapy for patients with multiple myeloma who underwent autologous hematopoietic stem cell transplant. Read more.
  • Treatment at higher-volume facilities may result in a lower risk for death in patients with multiple myeloma. Read more.
  • Single-agent therapy with daratumumab (Darzalex, Janssen) conferred encouraging efficacy and favorable safety in patients with heavily pretreated, refractory multiple myeloma. Read more.